Mirion Shorts Are Heavy, But Bulls Hold the Upside Case
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
MIR heads into its Q2 print today with short sellers firmly entrenched — yet options traders are tilting decisively the other way.
Short interest is genuinely elevated at 15.1% of the free float, with roughly 34.6 million shares sold short. That position has grown about 5.6% over the past month, even as it ticked fractionally lower in the most recent session. Days to cover runs nearly ten, meaning any rapid unwind would take time. Despite that heavy positioning, the borrow market shows no signs of stress: cost to borrow is minimal at 0.48%, and availability is ample at roughly 280% — meaning lenders have nearly three shares available for every one already borrowed. Shorts are not being squeezed out; they are sitting comfortably. The ORTEX short score of 69.4 places MIR in the bottom few percentiles of the universe on both short interest and days-to-cover ranks, confirming this is one of the more heavily shorted mid-cap names in the electronic equipment space.
Options positioning tells the opposite story. Demand for calls has surged relative to puts — the put/call ratio has collapsed to 0.05, nearly two and a half standard deviations below its 20-day average of 0.086, and within a whisker of the 52-week low. That is about as bullish a skew as options traders have shown all year, suggesting a meaningful cohort is positioned for upside from the print rather than protection against a miss.
The analyst community has been trimming targets steadily since February, with Goldman Sachs and Morgan Stanley both reducing to $25 in early-to-mid July while holding their respective Buy and Equal-Weight ratings. The broader consensus still sits at $27.40 — implying roughly 63% upside from the current price of $16.79 — but that gap reflects persistent stock weakness more than analyst optimism. The bull case centres on nuclear power demand: MIR's Nuclear Power segment grew 17.6% year-over-year in the most recent reported period, and adjusted EBITDA margins expanded meaningfully. Bears counter with a deteriorating backlog — down 3.4% year-over-year as of Q1 2025 — and softening demand in industrial and defense verticals. The stock is down 9% over the past month and has underperformed the broader market over six months, keeping momentum scores deeply negative despite some positive earnings-revision trends from analysts.
Past earnings reactions have been mixed in direction but not in magnitude. The May 2026 print produced a 0.2% decline on the day but a 4.9% fall over the following five sessions. The April 2026 report swung the other way, gaining 5.7% on the day and 9.2% over five days. Today's print will test whether the nuclear end-market strength is enough to stabilise the backlog picture — and whether that gap between a $16.79 stock and a $27 consensus is a buying opportunity or a valuation trap that the Street has yet to fully close.
Stocks in this article
See the live data behind this article on ORTEX.
Open MIR on ORTEX →How this article was generated
- Generated
- 29 Jul 2026, 04:33
- Data as of
- 29 Jul 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.